Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib

Lozano-Cuenca, Jair; Castañeda‐Hernández, Gilberto; Granados‐Soto, Vinicio

doi:10.1016/j.ejphar.2005.02.049

Cited by 37 publications

(48 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opioid analgesics exert an antinociceptive effect in both phases [20,28]. In contrast, NSAIDs suppress only the second phase [19,20,26]. In the present study, as previously shown lumiracoxib was ineffective in the first phase of the formalin test [18][19][20].…”

Section: Discussionsupporting

confidence: 72%

“…In contrast, NSAIDs suppress only the second phase [19,20,26]. In the present study, as previously shown lumiracoxib was ineffective in the first phase of the formalin test [18][19][20]. On the other hand, local peripheral administration of lumiracoxib was able to decrease the second phase of the formalin test.…”

Section: Discussionsupporting

confidence: 58%

“…Lumiracoxib appears to be more than a selective COX-2 inhibitor. Our group has demonstrated that lumiracoxib exhibits additional mechanisms of antinociception, particularly the activation of the nitric oxide (NO)-cyclic GMP-potassium channel pathway at the peripheral level on the formalin test [19]. Recently, it was demonstrated that lumiracoxib concentration-dependently and selectively inhibited the contraction responses to TP receptor agonists such as prostaglandin D2 and U-46619 in the tested smooth muscle preparations and the aggregation of human platelets [24].…”

Section: Introductionmentioning

confidence: 99%

“…Similarly, lumiracoxib decreased the mechanical hyperalgesia in a model of bone cancer pain in the rat and the nociception in the rat orofacial and paw formalin tests [17][18][19][20]. At clinical level, lumiracoxib is effective for the symptomatic treatment of osteoarthritis and/or acute pain related to primary dysmenorrhea and dental or orthopedic surgery [13,21,22].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats

Ortiz¹

2011

TOPAINJ

View full text Add to dashboard Cite

Abstract:It has been shown that the association of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic agents can increase their antinociceptive activity, allowing the use of lower doses and thus limiting side effects. Therefore, the aim of the present study was to examine the possible pharmacological interaction between lumiracoxib and lidocaine at the local peripheral level in the rat using the 1% formalin test and isobolographic analysis. Lumiracoxib, lidocaine or fixed-dose ratio (1:1) lumiracoxib-lidocaine combinations were administered locally in the formalin-injured paw and the antinociceptive effect was evaluated. All treatments produced a dose-dependent antinociceptive effect. ED 40 values were estimated for the individual drugs and an isobologram was constructed. The derived theoretical ED 40 for the lumiracoxiblidocaine combination was 599.3 ± 58.8 g/paw, being significantly higher than the actually observed experimental ED 40 value, 393.6 ± 39.7 g/paw. This result correspond to a synergistic interaction between lumiracoxib and lidocaine at the local peripheral level, potency being about one and half times higher with regard to that expected from the addition of the effects of the individual drugs. Data suggest that low doses of the lumiracoxib-lidocaine combination can interact synergistically at the peripheral level and therefore this drug association may represent a therapeutic advantage for the clinical treatment of procedural or inflammatory pain.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionsupporting

confidence: 58%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats

Ortiz¹

2011

TOPAINJ

View full text Add to dashboard Cite

show abstract

“…However, there is growing evidence that the antinociceptive effect of rofecoxib involves the activation of GMP-K + channel pathway (Deciga-Campos and Lopez-Munoz, 2004) and serotoninergic pathway (Sandrini et al, 2002). Recent studies suggest that diclofenac and lumiracoxib induced peripheral antinociception through the activation of the NOcyclic GMP pathway (Lozano-Cuenca et al, 2005).…”

Section: Antinociceptive Effects Of the Combination Of Cannabinoids Wmentioning

confidence: 99%

Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides?

Guindon

LoVerme

Léan

et al. 2006

European Journal of Pharmacology

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit fatty-acid amide hydrolase (FAAH), the enzyme responsible for the metabolism of anandamide, an endocannabinoid. It has been suggested that the mechanisms of action of NSAIDs could be due to inhibition of cyclooxygenase (COX) and also to an increase in endocannabinoid concentrations. In a previous study we have demonstrated that the local analgesic interaction between anandamide and ibuprofen (a non-specific COX inhibitor) was synergistic for the acute and inflammatory phases of the formalin test. To test this hypothesis further, we repeated similar experiments with rofecoxib (a selective COX-2 inhibitor) and also measured the local concentrations of anandamide, and of two fatty-acid amides, oleoylethanolamide and palmitoylethanolamide. We established the ED 50 for anandamide (34.52 pmol ± 17.26) and rofecoxib (381.72 pmol ± 190.86) and showed that the analgesic effect of the combination was synergistic. We also found that paw tissue levels of anandamide, oleoylethanolamide and palmitoylethanolamide were significantly higher when anandamide was combined with NSAIDs and that this effect was greater with rofecoxib. In conclusion, local injection of anandamide or rofecoxib was antinociceptive in a test of acute and inflammatory pain and the combination of anandamide with rofecoxib was synergistic. Finally, locally injected anandamide with either NSAID (ibuprofen or rofecoxib) generates higher amount of fatty-acid ethanolamides. The exact comprehension of the mechanisms involved needs further investigation.

show abstract

Synergistic interaction between B vitamins and statins to counter nociception in rats

López-Canales

Estefania

Carolina

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Evidence suggests that the antinociceptive activity of various drugs can be increased when administered in combination with B vitamins (BVs). The aim of this study was to examine the potential interaction between statins and BVs to counter nociception, the latter measured by the formalin test. Rats were orally administered atorvastatin (1, 3, 10 and 30 mg/kg), pravastatin (1, 3, 10 and 30 mg/kg), rosuvastatin (1, 3, 10 and 30 mg/kg), BVs (31, 56, 100 and 180 mg/kg) or calculated combinations of BVs with each drug. The effective dose 30 (ED30) was calculated for each statin and BVs and subjected to isobolographic analysis, thus finding the ED30 of the combinations. The antinociceptive experimental ED30 values for BVs administered with atorvastatin, pravastatin or rosuvastatin were 1.53 ± 0.38, 6.74 ± 0.04 and 4.26 ± 0.39, respectively, being lower (p < .05) than the corresponding theoretical ED30: 28.02 ± 2.20, 28.17 ± 2.20 and 29.86 ± 2.21. Since BVs likely boost the antinociceptive effect of statins, these combinations could possibly be advantageous in pain management.

show abstract

Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib

Cited by 37 publications

References 65 publications

Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats

Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats

Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides?

Synergistic interaction between B vitamins and statins to counter nociception in rats

Contact Info

Product

Resources

About